Koers Nile Therapeutics, Inc. Other OTC
Aandelen
US6541451018
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 22,24 mln. 20,68 mln. | Omzet 2025 * | 48,5 mln. 45,09 mln. | Marktkapitalisatie | 167 mln. 155 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -38 mln. -35,33 mln. | Nettowinst (verlies) 2025 * | -29 mln. -26,96 mln. | EV/omzet 2024 * | 7,49 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,44 x |
K/w-verhouding 2024 * |
-4,45
x | K/w-verhouding 2025 * |
-5,95
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,74% |
Recentste transcriptie over Nile Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20-11-13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20-11-13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21-07-23 |
Earl Collier
BRD | Director/Board Member | 76 | 20-11-13 |
George Dunbar
BRD | Director/Board Member | 77 | 20-11-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,23% | 125 mld. | |
+13,49% | 108 mld. | |
-7,33% | 24,21 mld. | |
+2,07% | 22,78 mld. | |
-10,79% | 17,96 mld. | |
-41,74% | 16,43 mld. | |
-13,51% | 16,37 mld. | |
+1,13% | 13,58 mld. | |
+27,75% | 11,66 mld. |
- Beurs
- Aandelen
- Koers CAPR
- Koers